Top Chicago, IL Health Tech Companies With Best Stability & Growth (491)

Innovation-Driven Growth: Regulatory milestones include FDA 510(k) clearance for the eVO2peak Module alongside multiple FDA‑cleared algorithms, signaling validated advancements in the product suite. AI analytics and quality certifications (ISO 13485/MDSAP) are positioned to support wider clinical and commercial deployment.

Investor Backing & Capital Strength: The March 2025 acquisition by Kardigan is presented as integrating Prolaio into a larger heart‑health platform that expands resources, customers, and reach. Being a Kardigan subsidiary with platform‑level integration into cardiovascular trials indicates ongoing backing for scale.

Market Expansion: Operations are cited across 20+ countries with indications of further expansion, reflecting a widening footprint and maturing deployment. The combined Prolaio–Kardigan platform is positioned to reach more patients, researchers, and biopharma partners globally.

Strong Revenue Growth: Revenue momentum is described as surpassing $200M in annual recurring revenue with sustained hypergrowth over five years as of mid-2026. These disclosures are presented alongside press coverage as the clearest signal of rapid expansion.

Investor Backing & Capital Strength: Capital scale is underscored by a $250M Series E led by Andreessen Horowitz in 2025 and sizeable total funding, paired with a multibillion-dollar valuation cited in coverage. This late-stage financing is tied to expansion plans in healthcare and housing as well as hiring and office growth.

Strong Market Position & Advantage: Adoption signals point to broad penetration in U.S. multifamily, including widespread use among large operators and a meaningful share of apartments nationwide. High-visibility distribution and portfolio rollouts reinforce a defensible position in its core market.

Strong Revenue Growth: Revenue is reported to have more than doubled two years in a row, with customer gains that tripled sales, indicating rapid topline momentum ahead of the 2026 acquisition.

Market Expansion: Multiple manufacturers are described as migrating to the Truzo platform and the offering broadened to span 340B and other programs, signaling wider adoption and influence.

Investor Backing & Capital Strength: Funding activity continued through 2024–2025 with investor support sustained prior to the 2026 acquisition, suggesting solid access to capital during scaling.

Product Line Growth: The launch of a dedicated Platform & Products unit and expansions of the ZAIDYN platform (including new agentic‑AI suites) indicate a deliberate shift toward scalable, productized offerings. These moves suggest expanding monetization levers beyond traditional consulting.

Market Expansion: Headcount and office count have risen, with a global footprint now spanning 40+ locations and new capacity in Hyderabad and Chicago. Inorganic moves such as the acquisition of Salesforce specialist Torrent Consulting extend reach in key healthcare cloud markets.

Strong Market Position & Advantage: Consistent Leader placements by Everest Group and IDC across life‑sciences and analytics services point to competitive strength in core domains. This positioning aligns with indications of healthy demand for ZS’s specialized offerings.

Strong Market Position & Advantage: PatientPoint is described as the nation’s largest digital point‑of‑care network, citing roughly 30,000–35,000 physician offices and about 145,000 screens, signaling outsized scale. Expanded Media Rating Council accreditation in April 2026 across its full screen network can further strengthen advertiser confidence and budgets.

Product Line Growth: In 2026 the company launched programmatic buying via PatientPoint Health Audiences and introduced a Consumer Health Network for CPG/OTC brands, broadening monetization avenues. These moves are positioned to expand the addressable revenue beyond traditional pharma channels.

Investor Backing & Capital Strength: Advent International signed a definitive agreement to acquire PatientPoint in August 2025, framed as a catalyst to accelerate network expansion and product innovation. Such backing is presented as a strong vote of confidence in both the company and the point‑of‑care media category.

Strong Revenue Growth: Revenue is reported at about $1.27B for 2025 (~80–83% YoY), with Q4 2025 at $367.2M (+83% YoY) and Q1 2026 at $348.1M (+36% YoY); full‑year 2026 is guided to $1.59–$1.60B (~25% growth). Segment data show Diagnostics up 34.7% and Data & Applications up 40.5% YoY in Q1 2026.

Strategic Partnerships: Record total contract value exceeding $1.1B and multi‑year collaborations with AstraZeneca, Merck, Gilead, and Bristol Myers Squibb are highlighted. These arrangements support growth in data/software lines and add forward revenue visibility.

Product Line Growth: MRD testing reached ~6,500 in Q1 2026 (up ~500% YoY), and acquisitions of Ambry Genetics, Paige.AI, and Deep 6 AI broaden testing and AI capabilities. Management points to horizontal integration and cross‑selling (e.g., with Ambry) as contributors to expected growth.

Innovation-Driven Growth: Product updates and launches, including AI features and benchmarking reports, appear on a frequent cadence, signaling ongoing investment in new capabilities and data-driven tools. This pattern suggests a forward-leaning roadmap aligned to emerging needs in assisted living.

Strategic Partnerships: An expanding ecosystem of integrations and recently added partners across payments, remote monitoring, and other categories points to a platform strategy that deepens utility and stickiness. This breadth of connections indicates growing interoperability within senior-living tech stacks.

Product Line Growth: The offering has broadened from a clinical EHR into an operating platform spanning CRM, billing, analytics, and AI, indicating increased coverage of operator workflows. Such expansion reflects efforts to capture more of the value chain within assisted-living operations.

Market Expansion: Roper combined Syntellis Performance Solutions with Strata in August 2023 and Strata acquired c. myers in July 2026, extending reach into financial institutions and higher education beyond its healthcare core. These moves add established footprints and capabilities in adjacent sectors.

Innovation-Driven Growth: Strata introduced new offerings such as AI-driven Predictive Analytics (March 31, 2026) and Position Control (2025) while announcing a Snowflake collaboration (March 3, 2025) to scale growing data needs. These launches and partnerships indicate ongoing product investment and platform expansion.

Strong Market Position & Advantage: Solutions have maintained Best in KLAS recognition (e.g., 2024 awards for Business Decision Support and FP&A, and 2025 leadership in Decision Support). This enduring category leadership signals sustained adoption and customer satisfaction.

Strong Market Position & Advantage: AbbVie ranks among the largest global pharma companies, is cited as the leading pharma by U.S. market revenue, and holds category leadership in immunology and medical aesthetics, reinforcing competitive leverage. Its scale supports R&D investment, commercialization reach, and payer negotiations in the largest market.

Strong Revenue Growth: Recent results show clear acceleration, with FY2025 revenue up from 2024 and Q1 2026 growing double digits year over year alongside a raised full-year 2026 EPS outlook. Management also reaffirmed expectations for a high single-digit revenue CAGR through 2029.

Diversified Revenue Streams: Skyrizi and Rinvoq drive immunology momentum while neuroscience (e.g., Vraylar, Botox Therapeutic, Ubrelvy, Qulipta), oncology (e.g., Venclexta, Elahere), and Allergan Aesthetics add additional cash‑flow sources. Recent acquisitions (ImmunoGen, Cerevel) and new manufacturing investments further broaden the base beyond immunology.

Market Expansion: The company reports growing from about 25,000 patients in 335 facilities (2019) to caring for more than 36,000 people across 500+ centers in 32–33 states, indicating a larger national footprint. Continued openings and 200+ home programs suggest expansion across both in‑center and home modalities.

Investor Backing & Capital Strength: USRC raised $328 million in 2023 and refinanced debt to lower interest costs and extend maturities, with proceeds positioned to fund expansion, home therapies, and value‑based care. Capital access has been used to scale home programs and value‑based initiatives.

Strategic Partnerships: Physician joint ventures underpin local market penetration and clinical alignment across the network. Multi‑year collaborations and the Kidneylink value‑based platform broaden capabilities in home dialysis and integrated kidney care.